Formulation: 200 μg of peptide in 200 μl TBS, pH 7.4, with 0.1% BSA and 0.02% sodium azide
Shelf life (days): 1095
Notes: To be used in conjunction with Cayman’s Soluble Epoxide Hydrolase polyclonal antibody (Catalog No.10010146) to block protein-antibody complex formation during analysis for soluble epoxide hydrolase. The metabolism of exogenous and endogenous epoxides relies in part upon the activity of soluble epoxide hydrolase (sEH).{830} The relevance of sEH to hypertension and inflammation makes it a potentially useful clinical drug target. Specifically, the conversion of epoxyeicosatrienoic acids (EpETrEs, EETs) by sEH to the corresponding dihydroxy eicosatrienoic acids (DiHETrEs, DHETs) diminishes their vasodilator activity.{12607} Inhibitors of sEH may therefore have clinical utility for treating hypertension and systemic inflammation.{14065,14072} Cayman · s polyclonal antibody is useful for monitoring the quantity and distribution of sEH.